Danaher (NYSE:DHR) Price Target Cut to $270.00

Posted by on Apr 28th, 2023

Danaher (NYSE:DHR – Get Rating) had its target price dropped by equities researchers at Credit Suisse Group from $300.00 to $270.00 in a research report issued on Wednesday, The Fly reports. Credit Suisse Group’s target price suggests a potential upside of 16.67% from the stock’s current price.

A number of other research analysts also recently commented on DHR. Wells Fargo & Company upgraded Danaher from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $275.00 to $285.00 in a research note on Tuesday, April 18th. Robert W. Baird cut their price objective on Danaher from $321.00 to $309.00 in a report on Wednesday, January 25th. Barclays reduced their target price on Danaher from $270.00 to $260.00 in a report on Wednesday. Cowen reduced their target price on Danaher from $340.00 to $320.00 and set an “outperform” rating for the company in a report on Wednesday, January 25th. Finally, StockNews.com started coverage on Danaher in a research report on Thursday, March 16th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $293.71.

Danaher Stock Performance

Shares of DHR opened at $231.42 on Wednesday. Danaher has a 52-week low of $227.00 and a 52-week high of $303.82. The company has a quick ratio of 1.52, a current ratio of 1.89 and a debt-to-equity ratio of 0.39. The firm has a market cap of $168.73 billion, a price-to-earnings ratio of 23.98, a PEG ratio of 1.90 and a beta of 0.80. The business’s 50 day moving average is $247.95 and its two-hundred day moving average is $257.21.

Danaher (NYSE:DHR – Get Rating) last issued its quarterly earnings results on Tuesday, April 25th. The conglomerate reported $2.36 earnings per share for the quarter, beating analysts’ consensus estimates of $2.26 by $0.10. Danaher had a return on equity of 17.02% and a net margin of 22.40%. The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.06 billion. During the same period in the previous year, the business earned $2.76 EPS. The business’s quarterly revenue was down 6.8% on a year-over-year basis. Analysts forecast that Danaher will post 10.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DHR. Arkadios Wealth Advisors increased its position in Danaher by 0.9% during the 4th quarter. Arkadios Wealth Advisors now owns 4,176 shares of the conglomerate’s stock worth $1,108,000 after buying an additional 37 shares during the period. Stonebridge Capital Advisors LLC increased its position in Danaher by 9.7% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 428 shares of the conglomerate’s stock worth $111,000 after buying an additional 38 shares during the period. Madison Wealth Partners Inc increased its position in Danaher by 0.7% during the 4th quarter. Madison Wealth Partners Inc now owns 5,284 shares of the conglomerate’s stock worth $1,402,000 after buying an additional 38 shares during the period. Sandy Cove Advisors LLC increased its position in Danaher by 0.7% during the 3rd quarter. Sandy Cove Advisors LLC now owns 5,540 shares of the conglomerate’s stock worth $1,431,000 after buying an additional 40 shares during the period. Finally, Donaldson Capital Management LLC increased its position in shares of Danaher by 3.3% in the fourth quarter. Donaldson Capital Management LLC now owns 1,260 shares of the conglomerate’s stock worth $334,000 after purchasing an additional 40 shares during the period. Institutional investors and hedge funds own 77.26% of the company’s stock.

About Danaher

(Get Rating)

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services.

Featured Stories

The Fly logo

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.